Genmab Phase 3 Trial of Rina-S Meets PFS and OS Endpoints
Genmab said the RAINFOL-02 trial met its progression-free and overall survival endpoints in platinum-resistant ovarian cancer. PFS hazard ratio was 0.29 in the ITT population and OS hazard ratio was 0.43; safety was consistent. The company plans regulatory discussions.
Genmab said the Phase 3 RAINFOL-02 trial of Rina-S in platinum-resistant ovarian cancer met its PFS and OS endpoints. In the ITT population, the hazard ratio was 0.29 for PFS and 0.43 for OS. Safety was consistent, and the company plans to hold regulatory discussions.